Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 Studies

• Published in: The international journal of neuropsychopharmacology 2024-11, Vol.27 (11), p.1
• Main Authors: Morrison, Randall L, Singh, Jaskaran, Daly, Ella, Fedgchin, Maggie, Ochs-Ross, Rachel, Karcher, Keith, Lane, Rosanne, Cooper, Kim, Sanacora, Gerard, Maruff, Paul, Drevets, Wayne C
• Format: Article
• Language: English
• Subjects: Administration, Intranasal; Adolescent; Adult; Aged; Antidepressive Agents - administration & dosage; Antidepressive Agents - pharmacology; Batteries; Clinical trials; Cognition; Cognition - drug effects; Comparative analysis; Depression, Mental; Depressive Disorder, Treatment-Resistant - drug therapy; Double-Blind Method; Drug therapy; Female; Health aspects; Humans; Ketamine - administration & dosage; Ketamine - pharmacology; Male; Middle Aged; Nasal Sprays; Product development; Regular; Respiratory agents; Young Adult
• ISSN: 1461-1457; 1469-5111; 1469-5111
• DOI: 10.1093/ijnp/pyae046

Abstract Background While esketamine is effective in treatment-resistant depression (TRD), detailed information about the effect of esketamine on cognition is relatively scarce. This analysis assessed the effect of short-term (3 double-blind [DB] studies: DB1, DB2, and DB4) or long-term maintenance treatment (DB3) with esketamine nasal spray (ESK) compared with a placebo (PBO) combined with active-comparator, on cognition in patients with TRD. Methods Patients (DB1/DB2/DB3: [18–64 years, n = 747]; DB4: [65 years or older, n = 137]) with TRD received ESK (DB1/DB2/DB3: 56/84 mg; DB4: 28/56/84 mg) or PBO+newly initiated oral antidepressant (OAD) as per treatment schedules. Cognitive assessments—Cogstate battery and Hopkins Verbal Learning Test-Revised—were administered at baseline, Day 28/early withdrawal, and follow-up visits in DB1/DB2/DB4 and at 12-week intervals in the DB3 maintenance phase. Descriptive statistics were used to analyze ESK effects on cognition with effect sizes and 95% confidence intervals to express the nature and magnitude of treatment effects relative to active-comparator+PBO. Correlation between depression severity (Montgomery-Ǻsberg Depression Rating Scale scores [MADRS]) and cognition was assessed at baseline and endpoint(s). Results At baseline, mild-to-moderate impairment in psychomotor function, attention, and memory (working and episodic) were evident. For each DB1/DB2/DB4, group mean performance in Z-scores for ESK+OAD and OAD+PBO groups on all cognitive tests remained similar or slightly improved from baseline at endpoint (Day 28) and follow-up assessments. Similarly, in DB3 (maintenance phase), both groups generally showed improvement in cognitive performance at endpoint(s). Correlations between MADRS scores and performance on the cognitive test battery were small at baseline and endpoint(s). Conclusions This analysis did not identify evidence of negative effects on cognition following short-term or long-term maintenance treatment with ESK+OAD in patients with TRD.